Journal
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Volume 41, Issue 3, Pages 495-500Publisher
SPRINGER
DOI: 10.1007/s10096-021-04388-y
Keywords
Klebsiella pneumoniae; Ceftazidime-avibactam; KPC
Categories
Funding
- Sapienza University of Rome [RM11916B6A8B5F8D]
Ask authors/readers for more resources
The aim of this study was to investigate ceftazidime-avibactam resistant and susceptible Klebsiella pneumoniae strains isolated from a patient with SARS-CoV2. The patient's condition, antimicrobial therapies, and microbiological data were collected. The study found the presence of highly conserved ST2502 strains producing KPC-31 and KPC-3, selected by CZA and carbapenem treatments, respectively, in the patient.
The objective was to study ceftazidime-avibactam resistant and susceptible Klebsiella pneumoniae isolated from a patient admitted to the Policlinico Umberto I of Rome for SARS-CoV2. Data on the evolution of patient's conditions, antimicrobial therapies, and microbiological data were collected. Whole-genome sequencing performed by Illumina and Nanopore sequencing methods were used to type the strains. During the hospitalization, a SARS-CoV2-infected patient was colonized by a KPC-producing K. pneumoniae strain and empirically treated with ceftazidime-avibactam (CZA) when presenting spiking fever symptoms. Successively, ST2502 CZA-resistant strain producing the KPC-31 variant gave a pulmonary infection to the patient. The infection was treated with high doses of meropenem. The KPC-31-producing strain disappeared but the patient remained colonized by a KPC-3-producing K. pneumoniae strain. An interplay between highly conserved KPC-31- and KPC-3-producing ST2502 strains occurred in the SARS-CoV2 patient during the hospitalization, selected by CZA and carbapenem treatments, respectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available